The Japan Lung Cancer Society guidelines recommend that all patients diagnosed with NSCLC should be tested for actionable biomarkers, including EGFR mutations, anaplastic lymphoma kinase rearrangements/fusion, and programmed cell death (ligand) 1 (PD-[L]1) expression [5,6]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.